Melane Sampson, Author at BioTuesdays

Developments

Sunshine receives approval for generic Enalapril in Canadian market

Sunshine BioPharma (NASDAQ: SBFM) has announced Canadian regulatory approval of its generic ACE inhibitor, Enalapril, in oral tablets of 2.5mg, 5mg, 10mg and 20mg for the treatment of hypertension, heart failure, and...

August 19, 2026

Developments

Revelation selects Avance Clinical as CRO for TITAN study

Revelation Biosciences (NASDAQ: REVB) has announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design...

August 19, 2026

Feature

AINGENS transforming complex scientific and medical workflows with evidence-first integrated AI solutions

Closely held AINGENS is addressing one of healthcare’s most persistent operational challenges—the costly, laborious process of transforming scientific data into compliant, actionable content. The company developed an...

August 18, 2026

Developments

FDA schedules Type A meeting for Ascelia’s Orviglance NDA

Ascelia Pharma (STO: ACE) has announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type A meeting for September 9, 2026 to discuss the Complete Response Letter (CRL) issued on July 2, 2026...

August 17, 2026

Developments

OmniAb and Eli Lilly collaborate on new ion channel program

OmniAb (NASDAQ: OABI) has announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for a new ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel...

August 17, 2026

Executive Moves

Defence appoints Dr. Ryan Simms as COO

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Ryan Simms, PhD, as chief operating officer (COO) and head of radiopharmaceutical programs, strengthening the company’s leadership and...

August 17, 2026

Developments

Profound’s new real-time interventional MRI software to pave the way for full ‘TULSA days’

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the introduction of its latest Treatment Delivery Console (TDC) software being deployed across Profound’s TULSA-PRO-installed base. According to Profound, the TDC...

August 17, 2026

Developments

Profound launches ‘Let’s Huddle’, a global community supporting men through prostate care

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the launch of Let’s Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every...

August 14, 2026

Developments

Intermountain Health becomes first to bring Perimeter’s Claire to the operating room

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Intermountain Health, in the Mountain West region, has become the first health system in the U.S. to commercially deploy Perimeter’s...

August 13, 2026

Executive Moves

Kamada transitions CFO; launches search for successor

Kamada (NASDAQ: KMDA; TASE: KMDA.TA) has announced that CFO Chaime Orlev will step down effective December 31, 2026, to pursue other opportunities and will provide transitional support to the incoming CFO. The company...

August 12, 2026

Author - Melane Sampson

Sunshine receives approval for generic Enalapril in Canadian market

Revelation selects Avance Clinical as CRO for TITAN study

AINGENS transforming complex scientific and medical workflows with evidence-first integrated AI solutions

FDA schedules Type A meeting for Ascelia’s Orviglance NDA

OmniAb and Eli Lilly collaborate on new ion channel program

Defence appoints Dr. Ryan Simms as COO

Profound’s new real-time interventional MRI software to pave the way for full ‘TULSA days’

Profound launches ‘Let’s Huddle’, a global community supporting men through prostate care

Intermountain Health becomes first to bring Perimeter’s Claire to the operating room

Kamada transitions CFO; launches search for successor

Subscribe